Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico
07:30am, Wednesday, 26'th Mar 2025
MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi® (tafasita
Why Incyte Stock Was Tanking This Week
11:56am, Friday, 21'st Mar 2025
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share
INCY Stock Down on Disappointing Skin Disease Study Data
04:00pm, Tuesday, 18'th Mar 2025
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
03:39pm, Tuesday, 18'th Mar 2025
Statistical significance achieved with both doses of povorcitinib in both phase 3 STOP-HS studies treating patients with Hidradenitis suppurativa. The global Hidradenitis Suppurativa market size is ex
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
12:30pm, Monday, 17'th Mar 2025
Shares of Incyte (INCY) sank nearly 10% Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
11:21am, Monday, 17'th Mar 2025
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Incyte Stock Eyes Worst Day Since 2018 After Trial Results
10:44am, Monday, 17'th Mar 2025
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effectiv
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
09:53am, Monday, 17'th Mar 2025
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 y
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:58am, Monday, 17'th Mar 2025
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Incyte's skin disease drug meets main goal in two late-stage studies
07:10am, Monday, 17'th Mar 2025
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
12:35pm, Wednesday, 12'th Mar 2025
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
11:56am, Monday, 10'th Mar 2025
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
10:15am, Monday, 10'th Mar 2025
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
01:00pm, Saturday, 08'th Mar 2025
Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant regrow
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN).
